1043 related articles for article (PubMed ID: 30587953)
1. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal.
Vanfleteren L; Fabbri LM; Papi A; Petruzzelli S; Celli B
Int J Chron Obstruct Pulmon Dis; 2018; 13():3971-3981. PubMed ID: 30587953
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
[TBL] [Abstract][Full Text] [Related]
3. Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide.
Singh D; Corradi M; Spinola M; Papi A; Usmani OS; Scuri M; Petruzzelli S; Vestbo J
Int J Chron Obstruct Pulmon Dis; 2017; 12():2917-2928. PubMed ID: 29062229
[TBL] [Abstract][Full Text] [Related]
4. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.
Rodrigo GJ; Price D; Anzueto A; Singh D; Altman P; Bader G; Patalano F; Fogel R; Kostikas K
Int J Chron Obstruct Pulmon Dis; 2017; 12():907-922. PubMed ID: 28360514
[TBL] [Abstract][Full Text] [Related]
5. The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials.
Lai CC; Chen CH; Lin CYH; Wang CY; Wang YH
Int J Chron Obstruct Pulmon Dis; 2019; 14():1539-1548. PubMed ID: 31371939
[TBL] [Abstract][Full Text] [Related]
6. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.
Mapel D; Laliberté F; Roberts MH; Sama SR; Sundaresan D; Pilon D; Lefebvre P; Duh MS; Patel J
Int J Chron Obstruct Pulmon Dis; 2017; 12():1825-1836. PubMed ID: 28684905
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis.
Bourdin A; Molinari N; Ferguson GT; Singh B; Siddiqui MK; Holmgren U; Ouwens M; Jenkins M; De Nigris E
Adv Ther; 2021 Jun; 38(6):3089-3112. PubMed ID: 33929661
[TBL] [Abstract][Full Text] [Related]
8. Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA/LABA inhalers?
Tariq SM; Thomas EC
Int J Chron Obstruct Pulmon Dis; 2017; 12():1877-1882. PubMed ID: 28694698
[TBL] [Abstract][Full Text] [Related]
9. Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review.
Langham S; Lewis J; Pooley N; Embleton N; Langham J; Han MK; Chalmers JD
Respir Res; 2019 Nov; 20(1):242. PubMed ID: 31684965
[TBL] [Abstract][Full Text] [Related]
10. LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes.
Hizawa N
Int J Chron Obstruct Pulmon Dis; 2015; 10():1093-102. PubMed ID: 26089659
[TBL] [Abstract][Full Text] [Related]
11. Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA.
Singh D; Fabbri LM; Vezzoli S; Petruzzelli S; Papi A
Int J Chron Obstruct Pulmon Dis; 2019; 14():531-546. PubMed ID: 30880943
[TBL] [Abstract][Full Text] [Related]
12. Comparative Effectiveness of Long-Acting Beta
Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
[TBL] [Abstract][Full Text] [Related]
13. Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β
Wang MT; Lai JH; Huang YL; Liou JT; Cheng SH; Lin CW; Pan HY; Hsu YJ; Tsai CL
Chest; 2021 Oct; 160(4):1255-1270. PubMed ID: 34023320
[TBL] [Abstract][Full Text] [Related]
14. Inhaled treatment of COPD: a Delphi consensus statement.
Ninane V; Corhay JL; Germonpré P; Janssens W; Joos GF; Liistro G; Vincken W; Gurdain S; Vanvlasselaer E; Lehouck A
Int J Chron Obstruct Pulmon Dis; 2017; 12():793-801. PubMed ID: 28293106
[TBL] [Abstract][Full Text] [Related]
15. Comparative Effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: Cohort Study in Real-World Clinical Practice.
Suissa S; Dell'Aniello S; Ernst P
Chest; 2020 Apr; 157(4):846-855. PubMed ID: 31759966
[TBL] [Abstract][Full Text] [Related]
16. Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects.
Malerba M; Nardin M; Santini G; Mores N; Radaeli A; Montuschi P
Ther Adv Respir Dis; 2018; 12():1753466618760779. PubMed ID: 29537340
[TBL] [Abstract][Full Text] [Related]
17. COPD treatment pathways in France: a retrospective analysis of electronic medical record data from general practitioners.
Meeraus W; Wood R; Jakubanis R; Holbrook T; Bizouard G; Despres J; Silva CCD; Nachbaur G; Landis SH; Punekar Y; Aguilaniu B; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2019; 14():51-63. PubMed ID: 30587961
[TBL] [Abstract][Full Text] [Related]
18. Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis.
Ismaila AS; Haeussler K; Czira A; Youn JH; Malmenäs M; Risebrough NA; Agarwal J; Nassim M; Sharma R; Compton C; Vogelmeier CF; Han MK; Halpin DMG
Adv Ther; 2022 Sep; 39(9):3957-3978. PubMed ID: 35849317
[TBL] [Abstract][Full Text] [Related]
19. Current appraisal of single inhaler triple therapy in COPD.
Lipworth B; Kuo CR; Jabbal S
Int J Chron Obstruct Pulmon Dis; 2018; 13():3003-3009. PubMed ID: 30319248
[TBL] [Abstract][Full Text] [Related]
20. Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD.
Albertson TE; Bowman WS; Harper RW; Godbout RM; Murin S
Int J Chron Obstruct Pulmon Dis; 2019; 14():1251-1265. PubMed ID: 31239659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
